TREATMENT AND PROGNOSIS OF MESANGIOPROLIFERATIVE GLOMERULONEPHRITIS(MePGN) INPATIENTS WITH NEPHROTIC SYNDROME(NS)

Wei M, He YY, Song HM

Peking Union Medical College Hospital, Beijing, China

Objective: To evaluate the therapeutic effects in the patients with MePGN (NS).

Methods: Clinical date from 51 patients with MePGN (NS) were collected and further analyzed retrospectively. The patients were treated with prednisone only, prednisone+glucosidorum tripterygll or prednisone +cyclophosphamide (CTX). All patients were followed up for 1 to 120 months for determining the therapeutic effects.

Results: 51 patients included 30 patients with IgA-MePGN (NS), and 21 patients with non-IgA- MePGN (NS). With different therapy, 29 patients (56.9%) remitted in two months; 33 patients (64.7%) completely remitted and 4 patients partly remitted, total remission rate was 86.3% in follow-up of average 15.4 months. The effect of therapy in IgA-MePGN was much better than in non-IgA-MePGN（P=0.015）. Comparing the therapeutic effect Among the patients with IgA-MePGN (NS), there was no different（P>0.05）in primary IgA nephropathy and in Henoch-Schonlein purpura nephritis (HSPN).

Conclusion: Steroids with or without other immunosuppressants showed good effects both in near future or in long term to the patients with MePGN (NS); The prognosis of IgA-MePGN(NS) could be better than non-IgA-MePGN (NS); There was no significant difference of therapeutic effects between primary IgA-MePGN (NS) and HSPN MePGN (NS).

0284